Following an initial Pre-Seed funding round in early 2025, TheraPPI has obtained a Growth Loan from Bpifrance. This non-dilutive financing will enable the company to continue developing its lead programme targeting the ERK/MyD88 interaction in the Ras-MAPK pathway, a novel drug target discovered by TheraPPI’s founders.
December 18, 2025 – Lyon, France and Geneva, Switzerland
TheraPPI Bioscience (“TheraPPI”), a preclinical biotechnology company focused on developing small molecules that modify protein-protein interactions, announced today that it has obtained from Bpifrance, a Growth loan (“Prêt Croissance”), which is a financing scheme aimed at strengthening the financial structure of SMEs and mid-cap companies undertaking a development programme.
TheraPPI will use the non-dilutive financing announced today to advance the development of its lead programme targeting ERK/MyD88, a novel protein interaction in the Ras-MAPK pathway. The goal is to combat resistance to cancer treatments and offer more effective and better tolerated therapies to patients with advanced cancers.
– ends –
Notes:
About TheraPPI drug programs:
TheraPPI’s first two programs target a novel MAPK protein interaction between ERK and MyD88, discovered by the founder team at the Centre de Recherche en Cancérologie de Lyon, France.
The prognosis of patients with advanced cancers remains poor, and up to 90% of cancer-related deaths are attributed to drug resistance. The MAPK signaling is hyperactivated in over 40% of human cancers, and MAPK-activating mutations are responsible for certain rare diseases. The efficacy of current MAPK Inhibitors is undermined by cancer resistance and by their inability to cure these rare diseases.
TheraPPI’s lead program, which targets ERK/MyD88 interaction, aims to achieve a high rate of clinical responses, overcome cancer resistance, and enhance the effectiveness of immunotherapies, ultimately offering a better prognosis for patients with advanced cancers.
About TheraPPI Bioscience:
TheraPPI is a preclinical-stage biotech company developing protein interaction-modifying drugs to provide patients with better treatments in oncology, rare diseases, and inflammatory conditions. TheraPPI consists of TheraPPI Bioscience SAS based in Lyon, France (“TheraPPI-France”) and TheraPPI Bioscience SA based in Geneva, Switzerland (“TheraPPI-Switzerland”).
TheraPPI-France was incubated within PULSALYS, Deeptech innovations incubator and accelerator in Lyon and Saint Etienne, France, and has been awarded the French Tech Emergence Grant by BPI France in the context of the “Programme France 2030”. In addition, TheraPPI -Switzerland received a FIF convertible loan from the Fondation Genevoise pour l’Innovation Technologique (“FONGIT”), Geneva, Switzerland, and closed a first closing of Pre-Seed Financing round.
For more information, please visit our website: https://tppibio.com/
Follow us on LinkedIn: https://www.linkedin.com/therappi-bioscience/
TheraPPI Bioscience SAS corporate address: 28 Rue Laennec, Centre Léon Bérard, 69008 Lyon, France
TheraPPI Bioscience SA corporate address: c/o Fondation Genevoise pour l’Innovation Technologique FONGIT, Route de la Galaise 34, 1228 Plan-les-Ouates, Switzerland
Bpifrance (https://www.bpifrance.fr/):
The Public Investment Bank (BPI France or bpifrance) was created in 2012 by the law of 31 December 2012.
Bpifrance finances and supports businesses – at every stage of their development – with loans, guarantees, innovation assistance and equity capital. In doing so, Bpifrance acts in support of public policies conducted by the State and the Regions.
Forward Looking Statements:
This press release includes forward-looking statements and assumptions which reflect the management’s current views of future events and operations. These forward-looking statements involve certain significant risks and uncertainties, and actual results may (negatively or positively) differ substantially from the forward-looking statements described explicitly or implicitly by TheraPPI.
Contact:
TheraPPI Bioscience
Luc Otten
CEO and co-founder
info@tppibio.com
Latest Posts
TheraPPI completes a first closing of Pre-Seed Financing to advance its lead oncology program targeting a novel protein interaction
TheraPPI announces publication of preclinical data in Nature Communications, demonstrating the inhibition of ERK/MyD88 interaction as a promising cancer treatment
TheraPPI Bioscience awarded the French Tech Emergence grant